Annexon (ANNX) Net Cash Flow (2019 - 2026)
Annexon (ANNX) posted quarterly Net Cash Flow of $13.2 million for Q1 2026, down 72.38% year-over-year from $47.6 million in Q1 2025, and down 41.87% quarter-over-quarter from $22.6 million in Q4 2025.
Annexon (ANNX) Net Cash Flow (2019 - 2026) Analysis & Trends
Annexon's Net Cash Flow history runs 8 years deep, the most recent figure standing at $13.2 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 72.38% year-over-year to $13.2 million; the TTM figure through Mar 2026 stood at $78.1 million (up 242.45% YoY), while the FY2025 annual figure was $112.6 million, up 164.1% from the prior year.
- Net Cash Flow for Q1 2026 stood at $13.2 million, down from $22.6 million in the prior quarter.
- The five-year high for Net Cash Flow was $106.0 million in Q3 2022, with the low at -$77.8 million in Q3 2024.
- The 5-year median for Net Cash Flow is $7.1 million (2025), against an average of $5.9 million.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow slumped 1882.14% in 2024, then jumped 555.8% in 2025.
- Annexon's Net Cash Flow stood at -$70.6 million in 2022, then jumped by 230.14% to $91.9 million in 2023, then plunged by 132.67% to -$30.0 million in 2024, then soared by 175.35% to $22.6 million in 2025, then sank by 41.87% to $13.2 million in 2026.
- Business Quant data shows ANNX's Net Cash Flow at $13.2 million in Q1 2026, $22.6 million in Q4 2025, and $7.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | 24.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.06 Mn |
| Jun 30, 2026 | 24.06 Mn |
| Mar 31, 2026 | 13.16 Mn |
| Mar 31, 2026 | 13.16 Mn |
| Dec 31, 2025 | 22.63 Mn |
| Dec 31, 2025 | 22.63 Mn |
| Sep 30, 2025 | 7.13 Mn |
| Sep 30, 2025 | 7.13 Mn |
| Jun 30, 2025 | 35.16 Mn |
| Jun 30, 2025 | 35.16 Mn |
| Mar 31, 2025 | 47.62 Mn |
| Mar 31, 2025 | 47.62 Mn |
| Dec 31, 2024 | -30.04 Mn |
| Dec 31, 2024 | -30.04 Mn |
| Sep 30, 2024 | -77.77 Mn |
| Sep 30, 2024 | -77.77 Mn |
| Jun 30, 2024 | 5.36 Mn |
| Jun 30, 2024 | 5.36 Mn |
| Mar 31, 2024 | -73.16 Mn |
| Mar 31, 2024 | -73.16 Mn |